OUR PIPELINE

MAKING
THE GREAT,
GREATER

We analyze the unmet needs of patients—continuously looking for ways to further improve therapies for those who need them. To help realize this goal, our teams have been hard at work to grow our portfolio of oncology, critical care, and orphan disease treatments through the development of biologics and small molecules.

THE TEAMS
AT WORK

Small Molecule Formulation Development

Mission Viejo, CA

Biologics Formulation Development

Cambridge, MA

Medical and Operations

Woodcliff Lake, NJ

Jupiter, FL

OUR PORTFOLIO AND PIPELINE CURRENTLY INCLUDES

RYANODEX® (dantrolene sodium) for Injectable Suspension

Learn more about RYANODEX and approved indications

Exertional Heat Stroke Investigational Indication
Clinical Trial Planned for August 2018

Psychostimulant Drug-Induced Toxicity Investigational Indication, Clinical Trial Ongoing

Nerve-Agent Induced Brain Damage Investigational Indication

Prescribing Information

PEMFEXY™ (pemetrexed injection)

Read about PEMFEXY’s tentative approval from the FDA

Fulvestrant

Hormone Receptor (HR)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced Breast Cancer, Who Have Gone Through Menopause and Have Not Been Previously Treated with Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive Advanced Breast Cancer, Who Have Gone Through Menopause and Whose Disease Has Progressed After Endocrine Therapy Investigational Indication, Clinical Trial Ongoing

HR-Positive, HER2-Negative Advanced Breast Cancer or Breast Cancer That Has Spread to Other Parts Of The Body (Metastatic), in Combination With Palbociclib or Abemaciclib in Women Whose Disease Has Progressed After Endocrine Therapy  Investigational Indication, Clinical Trial Ongoing